Meritage Portfolio Management Sells 658 Shares of Prestige Consumer Healthcare Inc. $PBH

Meritage Portfolio Management cut its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,044 shares of the company’s stock after selling 658 shares during the quarter. Meritage Portfolio Management’s holdings in Prestige Consumer Healthcare were worth $1,042,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Kayne Anderson Rudnick Investment Management LLC grew its stake in shares of Prestige Consumer Healthcare by 45.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after acquiring an additional 493,199 shares during the period. Invesco Ltd. grew its position in Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after buying an additional 261,537 shares during the period. Congress Asset Management Co. grew its position in Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock valued at $80,616,000 after buying an additional 18,015 shares during the period. Westwood Holdings Group Inc. grew its position in Prestige Consumer Healthcare by 7.1% during the first quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company’s stock valued at $74,044,000 after buying an additional 56,802 shares during the period. Finally, Northern Trust Corp grew its position in Prestige Consumer Healthcare by 4.8% during the first quarter. Northern Trust Corp now owns 852,274 shares of the company’s stock valued at $73,270,000 after buying an additional 39,198 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $60.91 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a 1-year low of $60.77 and a 1-year high of $90.04. The company has a market capitalization of $3.00 billion, a P/E ratio of 14.30, a P/E/G ratio of 1.93 and a beta of 0.44. The firm’s 50 day simple moving average is $65.27 and its two-hundred day simple moving average is $76.07.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $249.53 million during the quarter, compared to analysts’ expectations of $260.71 million. During the same period last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare’s quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PBH shares. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $94.80.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.